CSIMarket
 
Recursion Pharmaceuticals Inc   (NASDAQ: RXRX)
Other Ticker:  
 
 
Price: $4.8200 $0.11 2.335%
Day's High: $5.0899 Week Perf: 11.32 %
Day's Low: $ 4.68 30 Day Perf: 4.33 %
Volume (M): 34,940 52 Wk High: $ 12.36
Volume (M$): $ 168,408 52 Wk Avg: $5.75
Open: $4.98 52 Wk Low: $3.79



 Market Capitalization (Millions $) 2,154
 Shares Outstanding (Millions) 447
 Employees 500
 Revenues (TTM) (Millions $) 44
 Net Income (TTM) (Millions $) -716
 Cash Flow (TTM) (Millions $) 231
 Capital Exp. (TTM) (Millions $) 9

Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals Inc. is a biotechnology company that uses advanced artificial intelligence (AI), automation, and drug discovery platforms to develop new treatments for various diseases. The company focuses on identifying and targeting rare genetic diseases, as well as finding potential therapeutics for other complex diseases.

Recursion Pharmaceuticals utilizes high-throughput robotic imaging and combines it with deep learning algorithms to rapidly screen thousands of disease models in order to identify novel drug candidates. Their unique approach enables them to generate vast amounts of biological data that can be analyzed to uncover new insights and potential treatments.

The company has a diverse pipeline of drug candidates at various stages of development, covering a range of diseases like neurodegenerative disorders, cancer, and genetic diseases. They collaborate with pharmaceutical companies, academic institutions, and biotech partners to accelerate the discovery and development of new therapeutic options.

Recursion Pharmaceuticals aims to revolutionize drug discovery by integrating modern technology with biology to unlock new breakthroughs in treating diseases that were previously considered challenging. Their innovative approach holds the potential to provide hope for patients suffering from complex diseases and improve the overall efficiency of drug development.


   Company Address: 41 S Rio Grande Street Salt Lake City, 84101 UT
   Company Phone Number: 269 - 0203   Stock Exchange / Ticker: NASDAQ RXRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -5.06%    
BIIB        0.14% 
EXEL   -2.92%    
GILD   -2.2%    
MRNA        16.25% 
NBIX        1.65% 
• View Complete Report
   



Product Service News

In a notable advancement within the realm of computational biology, researchers at the Massach...

Published Fri, Jun 6 2025 3:40 PM UTC

Revolutionizing Biomolecular Research: MIT and Recursion Unveil Boltz-2 The Future of AI in Predicting Binding Affinity In a notable advancement within the realm of computational biology, researchers at the Massachusetts Institute of Technology (MIT) Computer Science and Artificial Intelligence Lab (CSAIL) and Jameel Clinic have launched Boltz-2, a groundbreaking biomolec...

Announcement

Recursion Pharmaceuticals Faces Stock Slump Ahead of Investor Conferences,

Published Tue, May 6 2025 12:35 PM UTC

Recursion Pharmaceuticals to Attend Upcoming Investor Conferences Amidst Recent Stock StrugglesSalt Lake City, May 6, 2025 Recursion Pharmaceuticals Inc. (Nasdaq: RXRX), a pioneering TechBio company focused on decoding biology to significantly enhance lives, announced today its engagement in several upcoming investor conferences. This announcement comes as the company gr...

Announcement

Pioneering Hope Recursion Pharmaceuticals Advances Dual Oncology Innovators to Clinical Trials

Published Tue, Jan 7 2025 2:23 PM UTC

In the ever-evolving landscape of oncology, where the fight against cancer intensifies day by day, Recursion Pharmaceuticals, a beacon in the TechBio industry, recently emerged as a frontrunner with its groundbreaking announcement. As of January 7, 2025, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has ushered in a new era of hope by clearing the clinica...

Announcement

Recursion Pharmaceuticals Grants Inducement Awards Amid Ongoing Market Challenges

Published Fri, Dec 20 2024 9:05 PM UTC

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a pioneering TechBio company known for its innovative approaches to drug discovery, has recently announced the approval of a substantial grant of inducement restricted stock unit (RSU) awards. On December 19, 2024, the Compensation Committee of Recursion s Board of Directors sanctioned the allocation of 7,952,836 shares of Clas...

Clinical Study

Emerging Evidence for REC-617 A Potential Breakthrough in CDK7 Inhibition for Advanced Solid Tumors,

Published Mon, Dec 9 2024 11:00 PM UTC

Promising Phase 1 Data Unveils REC-617: A Potential Game-Changer in CDK7 Inhibition for Solid TumorsOn December 9, 2024, Recursion Pharmaceuticals Inc. marked a significant milestone in oncology research with the interim results from their Phase 1/2 ELUCIDATE study, exploring the efficacy and safety of REC-617, a selective CDK7 inhibitor. As a drug that may represent a new ...







Recursion Pharmaceuticals Inc's Segments
Reportable Segment    100 % of total Revenue
United States    21.45 % of total Revenue
United Kingdom    78.55 % of total Revenue





Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.